A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA			
AGE/ GENDER	: 63 YRS/FEMALE	PATI	ENT ID	: 1612757
COLLECTED BY	:	REG.	NO./LAB NO.	: 122504050013
REFERRED BY	:	REGIS	STRATION DATE	: 05/Apr/2025 11:18 AM
BARCODE NO.	: 12507915	COLL	ECTION DATE	:05/Apr/2025 11:37AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPO	RTING DATE	:05/Apr/202501:23PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA (CITY - HARYANA	ł	
Test Name	V	alue	Unit	Biological Reference interval
	SWASTHY	A WELLN	ESS PANEL: 1.	0
		TE BLOOD	COUNT (CBC)	
	LS (RBCS) COUNT AND INDICES	10.7		10.0 16.0
HAEMOGLOBIN (H by CALORIMETRIC	В)	12.7	gm/dL	12.0 - 16.0
RED BLOOD CELL	(RBC) COUNT OCUSING, ELECTRICAL IMPEDENCE	3.95	Millions/	cmm 3.50 - 5.00
PACKED CELL VOI	LUME (PCV)	37.3	%	37.0 - 50.0
	UTOMATED HEMATOLOGY ANALYZER	94.5	fL	80.0 - 100.0
by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER MEAN CORPUSCULAR HAEMOGLOBIN (MCH)		32.1	Da	27.0 - 34.0
	UTOMATED HEMATOLOGY ANALYZER	32.1	pg	27.0 - 34.0
	LAR HEMOGLOBIN CONC. (MCHC) UTOMATED HEMATOLOGY ANALYZER	34	g/dL	32.0 - 36.0
RED CELL DISTRI	BUTION WIDTH (RDW-CV) UTOMATED HEMATOLOGY ANALYZER	12.9	%	11.00 - 16.00
	BUTION WIDTH (RDW-SD) UTOMATED HEMATOLOGY ANALYZER	45.5	fL	35.0 - 56.0
MENTZERS INDEX		23.92	RATIO	BETA THALASSEMIA TRAIT
by CALCOLATED				13.0 IRON DEFICIENCY ANEMIA
				>13.0
GREEN & KING IN by CALCULATED	DEX	90.71	RATIO	BETA THALASSEMIA TRAIT <= 65.0
				IRON DEFICIENCY ANEMIA
				65.0
WHITE BLOOD C				1000 11000
•	ΓΕ COUNT (TLC) ′ by sf cube & microscopy E UCOCYTE COUNT (DLC)	6670	/cmm	4000 - 11000
<u>DIFFERE</u> NTIAL LI				

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

NOT VALID FOR MEDICO LEGAL PURPOSE



PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana) A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA		
AGE/ GENDER	: 63 YRS/FEMALE	PATIENT ID	: 1612757
COLLECTED BY	:	REG. NO./LAB NO.	: 122504050013
REFERRED BY	:	REGISTRATION DATE	: 05/Apr/2025 11:18 AM
BARCODE NO.	: 12507915	COLLECTION DATE	: 05/Apr/2025 11:37AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 05/Apr/2025 01:23PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - H	IARYANA	

Test Name	Value	Unit	Biological Reference interval
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			
LYMPHOCYTES by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	28	%	20 - 40
EOSINOPHILS	4	%	1 - 6
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	-	70	1 - 0
MONOCYTES	6	%	2 - 12
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			
BASOPHILS by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	0	%	0 - 1
ABSOLUTE LEUKOCYTES (WBC) COUNT			
ABSOLUTE NEUTROPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	4135	/cmm	2000 - 7500
ABSOLUTE LYMPHOCYTE COUNT	1868 ^L	/cmm	800 - 4900
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	18082	/ emm	000 1900
ABSOLUTE EOSINOPHIL COUNT	267	/cmm	40 - 440
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			
ABSOLUTE MONOCYTE COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	400	/cmm	80 - 880
ABSOLUTE BASOPHIL COUNT	0	/cmm	0 - 110
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	0	/emm	0 - 110
PLATELETS AND OTHER PLATELET PREDICT	IVE MARKERS.		
PLATELET COUNT (PLT)	155000	/cmm	150000 - 450000
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE			
PLATELETCRIT (PCT)	0.2	%	0.10 - 0.36
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE		a	c 5 0 1 0 0
MEAN PLATELET VOLUME (MPV) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	13 ^H	fL	6.50 - 12.0
PLATELET LARGE CELL COUNT (P-LCC)	71000	/cmm	30000 - 90000
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	,1000	, ••••••	
PLATELET LARGE CELL RATIO (P-LCR)	45.5 ^H	%	11.0 - 45.0
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE			
PLATELET DISTRIBUTION WIDTH (PDW) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	16.2	%	15.0 - 17.0
NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD			



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

NOT VALID FOR MEDICO LEGAL PURPOSE





【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA			
AGE/ GENDER	: 63 YRS/FEMALE	PATIE	NT ID	: 1612757
COLLECTED BY	:	REG. N	IO./LAB NO.	: 122504050013
REFERRED BY	:	REGIS	TRATION DATE	: 05/Apr/2025 11:18 AM
BARCODE NO.	: 12507915	COLLE	CTION DATE	: 05/Apr/2025 11:37AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITU	TE Repoi	RTING DATE	:05/Apr/202501:23PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBAL	LA CITY - HARYANA		
Test Name		Value	Unit	Biological Reference interval
	ERYTHROCY	TE SEDIMENT	TATION RATE	(ESR)
ERYTHROCYTE SH	EDIMENTATION RATE (ESR)	24 ^H	mm/1st hi	r 0 - 20
	GATION BY CAPILLARY PHOTOMETRY			
NITEDDDETATIONI.				
NTERPRETATION:		on indicates the nre	sence of inflammati	on associated with infection cancer and aut
1. ESR is a non-specif	ic test because an elevated result ofte	en indicates the pre	sence of inflammation	on associated with infection, cancer and aut
1. ESR is a non-specif mmune disease, but	ic test because an elevated result ofte does not tell the health practitioner e	exactly where the in	flammation is in the	body or what is causing it.
1. ESR is a non-specif mmune disease, but 2. An ESR can be affe as C-reactive protein	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides infla	exactly where the in mmation. For this re	flammation is in the eason, the ESR is typ	body or what is causing it. bically used in conjunction with other test su
 ESR is a non-specif mmune disease, but An ESR can be affease C-reactive protein This test may also 	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides infla be used to monitor disease activity an	exactly where the in mmation. For this re	flammation is in the eason, the ESR is typ	body or what is causing it.
 ESR is a non-specif mmune disease, but An ESR can be affer as C-reactive protein This test may also systemic lupus erythe 	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflar pe used to monitor disease activity an ematosus	exactly where the in mmation. For this re	flammation is in the eason, the ESR is typ	body or what is causing it. bically used in conjunction with other test su
 ESR is a non-specif mmune disease, but An ESR can be affe- as C-reactive protein This test may also systemic lupus erythe CONDITION WITH LON 	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflar be used to monitor disease activity an ematosus N ESR	exactly where the in mmation. For this re and response to there	flammation is in the eason, the ESR is typ apy in both of the ab	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a
 ESR is a non-specif mmune disease, but An ESR can be affe- as C-reactive protein This test may also I systemic lupus erythe CONDITION WITH LOV A low ESR can be see 	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflar be used to monitor disease activity an ematosus V ESR n with conditions that inhibit the norr	exactly where the in mmation. For this re- nd response to thera mal sedimentation of	flammation is in the eason, the ESR is typ apy in both of the ab	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a uch as a high red blood cell count
 ESR is a non-specif mmune disease, but An ESR can be affe- as C-reactive protein This test may also i Gondition WITH LOV A low ESR can be see (polycythaemia), sign 	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflar be used to monitor disease activity an ematosus N ESR n with conditions that inhibit the norr ificantly high white blood cell count (exactly where the in mmation. For this re- nd response to thera mal sedimentation of	flammation is in the eason, the ESR is typ apy in both of the ab	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a
1. ESR is a non-specif mmune disease, but 2. An ESR can be affe- as C-reactive protein 3. This test may also systemic lupus erythe CONDITION WITH LOV A low ESR can be see (polycythaemia), sign as sickle cells in sickl NOTE:	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflar be used to monitor disease activity an ematosus N ESR n with conditions that inhibit the norr ificantly high white blood cell count (e cell anaemia) also lower the ESR.	exactly where the in mmation. For this re and response to thera mal sedimentation of (leucocytosis), and	flammation is in the eason, the ESR is typ apy in both of the ab	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a uch as a high red blood cell count
1. ESR is a non-specif mmune disease, but 2. An ESR can be affer as C-reactive protein 3. This test may also systemic lupus erythe CONDITION WITH LOV A low ESR can be see (polycythaemia), sign as sickle cells in sickl NOTE: 1. ESR and C - reactive	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflat be used to monitor disease activity an ematosus N ESR n with conditions that inhibit the norr ificantly high white blood cell count (e cell anaemia) also lower the ESR. e protein (C-RP) are both markers of ir	exactly where the in mmation. For this re and response to thera mal sedimentation of (leucocytosis), and nflammation.	flammation is in the eason, the ESR is typ apy in both of the ab of red blood cells, su some protein abnor	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a uch as a high red blood cell count malities. Some changes in red cell shape (su
 ESR is a non-specif mmune disease, but An ESR can be affe as C-reactive protein This test may also I systemic lupus erythe CONDITION WITH LOV A low ESR can be see (polycythaemia), sign as sickle cells in sickl NOTE: ESR and C - reactive Generally, ESR doe 	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflat be used to monitor disease activity an ematosus N ESR n with conditions that inhibit the norr ificantly high white blood cell count (e cell anaemia) also lower the ESR. e protein (C-RP) are both markers of ir s not change as rapidly as does CRP. e	exactly where the in mmation. For this re and response to thera mal sedimentation of (leucocytosis), and inflammation.	flammation is in the eason, the ESR is typ apy in both of the at of red blood cells, su some protein abnor f inflammation or as	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a uch as a high red blood cell count malities. Some changes in red cell shape (su it resolves.
1. ESR is a non-specif mmune disease, but 2. An ESR can be affe as C-reactive protein 3. This test may also I systemic lupus erythe CONDITION WITH LOV A low ESR can be see (polycythaemia), sign as sickle cells in sickl NOTE: 1. ESR and C - reactive 2. Generally, ESR doe 3. CRP is not affected	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflat be used to monitor disease activity an ematosus V ESR n with conditions that inhibit the norr ificantly high white blood cell count (e cell anaemia) also lower the ESR. e protein (C-RP) are both markers of ir s not change as rapidly as does CRP, e by as many other factors as is ESR, ma	exactly where the in mmation. For this re- mal sedimentation of (leucocytosis), and inflammation. either at the start of aking it a better mar	flammation is in the eason, the ESR is typ apy in both of the at of red blood cells, su some protein abnor f inflammation or as ker of inflammation.	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a uch as a high red blood cell count malities. Some changes in red cell shape (su it resolves.
1. ESR is a non-specif mmune disease, but 2. An ESR can be affe- as C-reactive protein 3. This test may also I systemic lupus erythe CONDITION WITH LOV A low ESR can be see (polycythaemia), sign as sickle cells in sickl NOTE: 1. ESR and C - reactive 2. Generally, ESR doe 3. CRP is not affected 4. If the ESR is elevate	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflar be used to monitor disease activity an ematosus V ESR n with conditions that inhibit the norr ificantly high white blood cell count (e cell anaemia) also lower the ESR. e protein (C-RP) are both markers of ir s not change as rapidly as does CRP, e by as many other factors as is ESR, ma ed, it is typically a result of two types	exactly where the in mmation. For this re- and response to thera mal sedimentation of (leucocytosis), and nflammation. either at the start of aking it a better mar of proteins, globuli	flammation is in the eason, the ESR is typ apy in both of the ab of red blood cells, su some protein abnor f inflammation or as ker of inflammation .	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a uch as a high red blood cell count malities. Some changes in red cell shape (su it resolves.
 ESR is a non-specify mmune disease, but An ESR can be affe- as C-reactive protein This test may also i Systemic lupus erythe CONDITION WITH LOV A low ESR can be see (polycythaemia), sign as sickle cells in sickli NOTE: ESR and C - reactive Generally, ESR doe B. CRP is not affected If the ESR is elevate Women tend to ha Drugs such as dext 	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflar be used to monitor disease activity an ematosus W ESR n with conditions that inhibit the norr ificantly high white blood cell count (e cell anaemia) also lower the ESR. e protein (C-RP) are both markers of ir s not change as rapidly as does CRP, e by as many other factors as is ESR, ma ed, it is typically a result of two types we a higher ESR, and menstruation and ran, methyldopa, oral contraceptives,	exactly where the in mmation. For this re- nd response to thera mal sedimentation of (leucocytosis), and inflammation. either at the start of aking it a better mar of proteins, globuling d pregnancy can cau	flammation is in the eason, the ESR is typ apy in both of the ab of red blood cells, su some protein abnor f inflammation or as ker of inflammation . ns or fibrinogen. ise temporary elevat	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a uch as a high red blood cell count rmalities. Some changes in red cell shape (su it resolves. tions.
 ESR is a non-specify mmune disease, but An ESR can be affe- as C-reactive protein This test may also i Systemic lupus erythe CONDITION WITH LOV A low ESR can be see (polycythaemia), sign as sickle cells in sickli NOTE: ESR and C - reactive Generally, ESR doe B. CRP is not affected If the ESR is elevate Women tend to ha Drugs such as dext 	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflar be used to monitor disease activity an ematosus V ESR n with conditions that inhibit the norr ificantly high white blood cell count (e cell anaemia) also lower the ESR. e protein (C-RP) are both markers of ir s not change as rapidly as does CRP, e by as many other factors as is ESR, ma ed, it is typically a result of two types ye a higher ESR. and menstruation and	exactly where the in mmation. For this re- nd response to thera mal sedimentation of (leucocytosis), and inflammation. either at the start of aking it a better mar of proteins, globuling d pregnancy can cau	flammation is in the eason, the ESR is typ apy in both of the ab of red blood cells, su some protein abnor f inflammation or as ker of inflammation . ns or fibrinogen. ise temporary elevat	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a uch as a high red blood cell count malities. Some changes in red cell shape (su it resolves.
 ESR is a non-specify mmune disease, but An ESR can be affe- as C-reactive protein This test may also i Systemic lupus erythe CONDITION WITH LOV A low ESR can be see (polycythaemia), sign as sickle cells in sickli NOTE: ESR and C - reactive Generally, ESR doe B. CRP is not affected If the ESR is elevate Women tend to ha Drugs such as dext 	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflar be used to monitor disease activity an ematosus W ESR n with conditions that inhibit the norr ificantly high white blood cell count (e cell anaemia) also lower the ESR. e protein (C-RP) are both markers of ir s not change as rapidly as does CRP, e by as many other factors as is ESR, ma ed, it is typically a result of two types we a higher ESR, and menstruation and ran, methyldopa, oral contraceptives,	exactly where the in mmation. For this re- nd response to thera mal sedimentation of (leucocytosis), and inflammation. either at the start of aking it a better mar of proteins, globuling d pregnancy can cau	flammation is in the eason, the ESR is typ apy in both of the ab of red blood cells, su some protein abnor f inflammation or as ker of inflammation . ns or fibrinogen. ise temporary elevat	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a uch as a high red blood cell count rmalities. Some changes in red cell shape (su it resolves. tions.
 ESR is a non-specify mmune disease, but An ESR can be affe- as C-reactive protein This test may also i Systemic lupus erythe CONDITION WITH LOV A low ESR can be see (polycythaemia), sign as sickle cells in sickli NOTE: ESR and C - reactive Generally, ESR doe B. CRP is not affected If the ESR is elevate Women tend to ha Drugs such as dext 	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflar be used to monitor disease activity an ematosus W ESR n with conditions that inhibit the norr ificantly high white blood cell count (e cell anaemia) also lower the ESR. e protein (C-RP) are both markers of ir s not change as rapidly as does CRP, e by as many other factors as is ESR, ma ed, it is typically a result of two types we a higher ESR, and menstruation and ran, methyldopa, oral contraceptives,	exactly where the in mmation. For this re- nd response to thera mal sedimentation of (leucocytosis), and inflammation. either at the start of aking it a better mar of proteins, globuling d pregnancy can cau	flammation is in the eason, the ESR is typ apy in both of the ab of red blood cells, su some protein abnor f inflammation or as ker of inflammation . ns or fibrinogen. ise temporary elevat	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a uch as a high red blood cell count rmalities. Some changes in red cell shape (su it resolves. tions.
 ESR is a non-specify mmune disease, but An ESR can be affe- as C-reactive protein This test may also i Systemic lupus erythe CONDITION WITH LOV A low ESR can be see (polycythaemia), sign as sickle cells in sickli NOTE: ESR and C - reactive Generally, ESR doe B. CRP is not affected If the ESR is elevate Women tend to ha Drugs such as dext 	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflar be used to monitor disease activity an ematosus W ESR n with conditions that inhibit the norr ificantly high white blood cell count (e cell anaemia) also lower the ESR. e protein (C-RP) are both markers of ir s not change as rapidly as does CRP, e by as many other factors as is ESR, ma ed, it is typically a result of two types we a higher ESR, and menstruation and ran, methyldopa, oral contraceptives,	exactly where the in mmation. For this re- nd response to thera mal sedimentation of (leucocytosis), and inflammation. either at the start of aking it a better mar of proteins, globuling d pregnancy can cau	flammation is in the eason, the ESR is typ apy in both of the ab of red blood cells, su some protein abnor f inflammation or as ker of inflammation . ns or fibrinogen. ise temporary elevat	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a uch as a high red blood cell count rmalities. Some changes in red cell shape (su it resolves. tions.
 ESR is a non-specify mmune disease, but An ESR can be affe- as C-reactive protein This test may also i Systemic lupus erythe CONDITION WITH LOV A low ESR can be see (polycythaemia), sign as sickle cells in sickli NOTE: ESR and C - reactive Generally, ESR doe B. CRP is not affected If the ESR is elevate Women tend to ha Drugs such as dext 	ic test because an elevated result ofte does not tell the health practitioner e cted by other conditions besides inflar be used to monitor disease activity an ematosus N ESR n with conditions that inhibit the norr ificantly high white blood cell count (e cell anaemia) also lower the ESR. e protein (C-RP) are both markers of ir s not change as rapidly as does CRP, e by as many other factors as is ESR, ma ed, it is typically a result of two types we a higher ESR, and menstruation and ran, methyldopa, oral contraceptives,	exactly where the in mmation. For this re- nd response to thera mal sedimentation of (leucocytosis), and inflammation. either at the start of aking it a better mar of proteins, globuling d pregnancy can cau	flammation is in the eason, the ESR is typ apy in both of the ab of red blood cells, su some protein abnor f inflammation or as ker of inflammation . ns or fibrinogen. ise temporary elevat	body or what is causing it. bically used in conjunction with other test su bove diseases as well as some others, such a uch as a high red blood cell count rmalities. Some changes in red cell shape (su it resolves. tions.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

NOT VALID FOR MEDICO LEGAL PURPOSE





A PIONEER DIAGNOSTIC CENTRE © 0171-2532620, 8222896961 ⊠ pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA			
AGE/ GENDER	: 63 YRS/FEMALE		PATIENT ID	: 1612757
COLLECTED BY	:		REG. NO./LAB NO.	: 122504050013
REFERRED BY	:		REGISTRATION DATE	: 05/Apr/2025 11:18 AM
BARCODE NO.	: 12507915		COLLECTION DATE	: 05/Apr/2025 11:37AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTI	TUTE	REPORTING DATE	: 05/Apr/2025 02:04PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AME	ALA CITY - HA	ARYANA	
Test Name		Value	Unit	Biological Reference interval
	PROTHI	ROMBIN T	IME STUDIES (PT/IN	R)
PT TEST (PATIEN' by PHOTO OPTICAL C	T)	11.7	SECS	11.5 - 14.5
PT (CONTROL) by PHOTO OPTICAL C		12	SECS	
ISI by PHOTO OPTICAL C	LOT DETECTION	1.1		
INTERNATIONAL by PHOTO OPTICAL C	NORMALISED RATIO (INR)	0.97		0.80 - 1.20

PT INDEX

by PHOTO OPTICAL CLOT DETECTION

<u>INTERPRETATION:</u> 1.INR is the parameter of choice in monitoring adequacy of oral anti-coagulant therapy. Appropriate therapeutic range varies with the disease and treatment intensity.

%

102.56

2. Prolonged INR suggests potential bleeding disorder /bleeding complications

3. Results should be clinically correlated.

4. Test conducted on Citrated Plasma

INDICATION	INDICATION		
Treatment of venous thrombosis			
Treatment of pulmonary embolism			
Prevention of systemic embolism in tissue heart valves			
Valvular heart disease	Low Intensity	2.0 - 3.0	
Acute myocardial infarction			
Atrial fibrillation			
Bileaflet mechanical valve in aortic position			
Recurrent embolism			
Mechanical heart valve	High Intensity	2.5 - 3.5	
Antiphospholipid antibodies ⁺]		

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)





🕻 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA		
AGE/ GENDER	: 63 YRS/FEMALE	PATIENT ID	: 1612757
COLLECTED BY	:	REG. NO./LAB NO.	: 122504050013
REFERRED BY	:	REGISTRATION DATE	: 05/Apr/2025 11:18 AM
BARCODE NO.	: 12507915	COLLECTION DATE	: 05/Apr/2025 11:37AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 05/Apr/2025 02:04PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY -	HARYANA	

|--|

The prothrombin time (PT) and its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) are measures of the efficacy of the extrinsic pathway of coagulation. PT test reflects the adequacy of factors I (fibrinogen), II (prothrombin), V, VII, and X. It is used in conjunction with the activated partial thromboplastin time (aPTT) which measures the intrinsic pathway. The common causes of prolonged prothrombin time are :

1.Oral Anticoagulant therapy.

2.Liver disease.

3.Vit K. deficiency.

4. Disseminated intra vascular coagulation.

5.Factor 5, 7, 10 or Prothrombin dificiency



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA				
AGE/ GENDER	: 63 YRS/FEMALE	PATI	ENT ID	: 1612	757
COLLECTED BY	:	REG.	NO./LAB NO.	: 1225	604050013
REFERRED BY	:	REGI	STRATION DATE	:05/Aj	pr/2025 11:18 AM
BARCODE NO.	: 12507915	COLL	ECTION DATE	:05/Aj	pr/2025 11:37AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE IN	ISTITUTE REPO	DRTING DATE	:05/Aj	pr/2025 01:23PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, A	AMBALA CITY - HARYAN	A		
Test Name		Value	Unit		Biological Reference interval
	CLINIC	CAL CHEMISTRY	Y/BIOCHEMIS	STRY	
		GLUCOSE FAS	STING (F)		
GLUCOSE FASTIN		125.73 ^H	mg/dL		NORMAL: < 100.0 PREDIABETIC: 100.0 - 125.0
by GLUCOSE OXIDAS	E - PEROXIDASE (GOD-POD)				DIABETIC: $> 0R = 126.0$

A fasting plasma glucose level below 100 mg/dl is considered normal.
 A fasting plasma glucose level between 100 - 125 mg/dl is considered as glucose intolerant or prediabetic. A fasting and post-prandial blood test (after consumption of 75 gms of glucose) is recommended for all such patients.
 A fasting plasma glucose level of above 125 mg/dl is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA			
AGE/ GENDER	: 63 YRS/FEMALE		PATIENT ID	: 1612757
COLLECTED BY	:		REG. NO./LAB NO.	: 122504050013
REFERRED BY	:		REGISTRATION DATE	:05/Apr/2025 11:18 AM
BARCODE NO.	: 12507915		COLLECTION DATE	: 05/Apr/2025 11:37AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE IN	STITUTE	REPORTING DATE	: 05/Apr/2025 01:23PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, A	MBALA CITY - H	ARYANA	
Test Name		Value	Unit	Biological Reference interval
		LIPID PR	OFILE : BASIC	
CHOLESTEROL TO by CHOLESTEROL O.		177.5	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0
TRIGLYCERIDES: by GLYCEROL PHOSI	SERUM PHATE OXIDASE (ENZYMATIC)	143.59	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0
HDL CHOLESTER	OL (DIRECT): SERUM Tion	44.38	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTER(by CALCULATED, SPI	DL: SERUM ECTROPHOTOMETRY	104.4	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0
NON HDL CHOLES	STEROL: SERUM ECTROPHOTOMETRY	133.12 ^H	mg/dL	VERY HIGH: > OR = 190.0 OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTER	ROL: SERUM ECTROPHOTOMETRY	28.72	mg/dL	0.00 - 45.00
TOTAL LIPIDS: SE		498.59	mg/dL	350.00 - 700.00
CHOLESTEROL/HI	DL RATIO: SERUM ECTROPHOTOMETRY	4	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST



PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana) A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA		
AGE/ GENDER	: 63 YRS/FEMALE	PATIENT ID	: 1612757
COLLECTED BY	:	REG. NO./LAB NO.	: 122504050013
REFERRED BY	:	REGISTRATION DATE	: 05/Apr/2025 11:18 AM
BARCODE NO.	: 12507915	COLLECTION DATE	: 05/Apr/2025 11:37AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	:05/Apr/202501:23PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY -	HARYANA	
-			
Test Name	Value	Unit	Biological Reference interval

			MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0
LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	2.35	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM	3.24	RATIO	3.00 - 5.00

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

 Cow HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
 NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA				
AGE/ GENDER	: 63 YRS/FEMALE		PATIENT ID	: 1612757	
COLLECTED BY	:		REG. NO./LAB NO.	: 122504050013	
REFERRED BY	:		REGISTRATION DATE	: 05/Apr/2025 11:18 AM	
BARCODE NO.	: 12507915		COLLECTION DATE	: 05/Apr/2025 11:37AM	
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUT	Έ	REPORTING DATE	: 05/Apr/2025 03:59PM	
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA	A CITY - H	IARYANA		
Test Name		Value	Unit	Biological Reference interv	
	LIVER FU	JNCTIO	ON TEST (COMPLETE)	
BILIRUBIN TOTAL by DIAZOTIZATION, SF	: SERUM PECTROPHOTOMETRY	0.39	mg/dL	INFANT: 0.20 - 8.00 ADULT: 0.00 - 1.20	
	T (CONJUGATED): SERUM	0.18	mg/dL	0.00 - 0.40	
BILIRUBIN INDIRE by CALCULATED, SPE	ECT (UNCONJUGATED): SERUM	0.21	mg/dL	0.10 - 1.00	
SGOT/AST: SERUM by IFCC, WITHOUT PY	I RIDOXAL PHOSPHATE	25.71	U/L	7.00 - 45.00	
SGPT/ALT: SERUM by IFCC, WITHOUT PY	I RIDOXAL PHOSPHATE	11 P	KR U/L	0.00 - 49.00	
AST/ALT RATIO: S by CALCULATED, SPE		2.34	RATIO	0.00 - 46.00	
ALKALINE PHOSPI by PARA NITROPHEN PROPANOL	HATASE: SERUM YL PHOSPHATASE BY AMINO METHYL	100.8	U/L	40.0 - 130.0	
GAMMA GLUTAM by SZASZ, SPECTROF	YL TRANSFERASE (GGT): SERUM PHTOMETRY	12.83	U/L	0.00 - 55.0	
TOTAL PROTEINS by BIURET, SPECTRO		6.55	gm/dL	6.20 - 8.00	
ALBUMIN: SERUM by BROMOCRESOL G		3.9	gm/dL	3.50 - 5.50	
GLOBULIN: SERUN by CALCULATED, SPE		2.65	gm/dL	2.30 - 3.50	
A : G RATIO: SERU	JM	1.47	RATIO	1.00 - 2.00	

by CALCULATED, SPECTROPHOTOMETRY

NOTE:- To be correlated in individuals having SGOT and SGPT values higher than Normal Referance Range.

USE:- Differential diagnosis of diseases of hepatobiliary system and pancreas.

INCREASED:

DRUG HEPATOTOXICITY	>2
ALCOHOLIC HEPATITIS	> 2 (Highly Suggestive)
CIRRHOSIS	1.4 - 2.0
INTRAHEPATIC CHOLESTATIS	> 1.5





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST



INTERPRETATION



【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA		
AGE/ GENDER	: 63 YRS/FEMALE	PATIENT ID	: 1612757
COLLECTED BY	:	REG. NO./LAB NO.	: 122504050013
REFERRED BY	:	REGISTRATION DATE	: 05/Apr/2025 11:18 AM
BARCODE NO.	: 12507915	COLLECTION DATE	: 05/Apr/2025 11:37AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 05/Apr/2025 03:59PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY -	- HARYANA	

Test Name	Value	Unit	Biological Reference interval
HEPATOCELLULAR CARCINOMA & CHRONIC HEPATITIS		> 1.3 (Slightly Increased)	
DECREASED:			

1. Acute Hepatitis due to virus, drugs, toxins (with AST increased 3 to 10 times upper limit of normal)

2. Extra Hepatic cholestatis: 0.8 (normal or slightly decreased).

PROGNOSTIC	SIGNIFICANCE:

NORMAL	< 0.65
GOOD PROGNOSTIC SIGN	0.3 - 0.6
POOR PROGNOSTIC SIGN	1.2 - 1.6



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST





A PIONEER DIAGNOSTIC CENTRE

🕻 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA				
AGE/ GENDER	: 63 YRS/FEMALE		PATIENT ID	: 1612757	
COLLECTED BY	:		REG. NO./LAB NO.	: 122504050013	
REFERRED BY			REGISTRATION DATE	: 05/Apr/2025 11:18 AM	
BARCODE NO.	: 12507915		COLLECTION DATE	: 05/Apr/2025 11:37AM	
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTIT	ΓUTE	REPORTING DATE	: 05/Apr/2025 03:59PM	
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMB	ALA CITY - HA	ARYANA		
Test Name		Value	Unit	Biological Reference interva	
	KIDNEY	Y FUNCTIO	ON TEST (COMPLETE	2)	
UREA: SERUM		29.22	mg/dL	10.00 - 50.00	
	ATE DEHYDROGENASE (GLDH)			0.40 1.00	
CREATININE: SERU by ENZYMATIC, SPECT		1	mg/dL	0.40 - 1.20	
•	ROGEN (BUN): SERUM	13.65	mg/dL	7.0 - 25.0	
by CALCULATED, SPEC					
BLOOD UREA NITROGEN (BUN)/CREATININE RATIO: SERUM		13.65 R	RATIO	10.0 - 20.0	
by CALCULATED, SPE	CTROPHOTOMETRY				
UREA/CREATININE		29.22	RATIO		
by CALCULATED, SPEC		4.21	mg/dL	2.50 - 6.80	
by URICASE - OXIDASE		4.21	liig/uL	2.50 - 0.80	
CALCIUM: SERUM		8.86	mg/dL	8.50 - 10.60	
by ARSENAZO III, SPEC PHOSPHOROUS: SE		3.43	mg/dL	2.30 - 4.70	
	ATE, SPECTROPHOTOMETRY	5.45	iiig/uL	2.30 - 4.70	
ELECTROLYTES					
SODIUM: SERUM		141.96	mmol/L	135.0 - 150.0	
by ISE (ION SELECTIVE		1.50		2.50 5.00	
POTASSIUM: SERU by ISE (ION SELECTIVE		4.52	mmol/L	3.50 - 5.00	
CHLORIDE: SERUM	[106.47	mmol/L	90.0 - 110.0	
by ISE (ION SELECTIVE		F			
	MERULAR FILTERATION RAT				
ESTIMATED GLOM (eGFR): SERUM	ERULAR FILTERATION RATE	63.3			
by CALCULATED					

INTERPRETATION:

To differentiate between pre- and post renal azotemia.

INCREASED RATIO (>20:1) WITH NORMAL CREATININE:

1. Prerenal azotemia (BUN rises without increase in creatinine) e.g. heart failure, salt depletion, dehydration, blood loss) due to decreased glomerular filtration rate.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



A PIONEER DIAGNOSTIC CENTRE

0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA		
AGE/ GENDER	: 63 YRS/FEMALE	PATIENT ID	: 1612757
COLLECTED BY	:	REG. NO./LAB NO.	: 122504050013
REFERRED BY	:	REGISTRATION DATE	: 05/Apr/2025 11:18 AM
BARCODE NO.	: 12507915	COLLECTION DATE	: 05/Apr/2025 11:37AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 05/Apr/2025 03:59PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - H	IARYANA	
Test Name	Value	Unit	Biological Reference interval

- 4. High protein intake.
- 5. Impaired renal function plus
- 6. Excess protein intake or production or tissue breakdown (e.g. infection, GI bleeding, thyrotoxicosis, Cushing's syndrome, high protein diet,
- burns, surgery, cachexia, high fever).
- 7. Urine reabsorption (e.g. ureter colostomy)
- 8. Reduced muscle mass (subnormal creatinine production)
- 9. Certain drugs (e.g. tetracycline, glucocorticoids)

INCREASED RATIO (>20:1) WITH ELEVATED CREATININE LEVELS:

1. Postrenal azotemia (BUN rises disproportionately more than creatinine) (e.g. obstructive uropathy).

2. Prerenal azotemia superimposed on renal disease.

DECREASED RATIO (<10:1) WITH DECREASED BUN :

- 1. Acute tubular necrosis.
- 2. Low protein diet and starvation.
- 3. Severe liver disease.
- 4. Other causes of decreased urea synthesis.
- 5. Repeated dialysis (urea rather than creatinine diffuses out of extracellular fluid).
- 6. Inherited hyperammonemias (urea is virtually absent in blood).
- 7. SIADH (syndrome of inappropiate antidiuretic harmone) due to tubular secretion of urea.
- 8. Pregnancy.

DECREASED RATIO (<10:1) WITH INCREASED CREATININE:

- 1. Phenacimide therapy (accelerates conversion of creatine to creatinine).
- 2. Rhabdomyolysis (releases muscle creatinine).
- 3. Muscular patients who develop renal failure.

INAPPROPIATE RATIO:

1. Diabetic ketoacidosis (acetoacetate causes false increase in creatinine with certain methodologies, resulting in normal ratio when dehydration should produce an increased BUN/creatinine ratio).

2. Cephalosporin therapy (interferes with creatinine measurement).

CKD STAGE	DESCRIPTION	GFR (mL/min/1.73m2)	ASSOCIATED FINDINGS
G1	Normal kidney function	>90	No proteinuria
G2	Kidney damage with normal or high GFR	>90	Presence of Protein , Albumin or cast in urine
G3a	Mild decrease in GFR	60 -89	
G3b	Moderate decrease in GFR	30-59	
G4	Severe decrease in GFR	15-29	
G5	Kidney failure	<15	





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA

CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA		
AGE/ GENDER	: 63 YRS/FEMALE	PATIENT ID	: 1612757
COLLECTED BY	:	REG. NO./LAB NO.	: 122504050013
REFERRED BY	:	REGISTRATION DATE	: 05/Apr/2025 11:18 AM
BARCODE NO.	: 12507915	COLLECTION DATE	:05/Apr/2025 11:37AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 05/Apr/2025 03:59PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - H	IARYANA	

Test Name	Value	Unit	Biological Reference interval

COMMENTS:

1. Estimated Glomerular filtration rate (eGFR) is the sum of filtration rates in all functioning nephrons and so an estimation of the GFR provides a measure of functioning nephrons of the kidney. 2. eGFR calculated using the 2009 CKD-EPI creatinine equation and GFR category reported as per KDIGO guideline 2012

3. In patients, with eGFR creatinine between 45-59 ml/min/1.73 m2 (G3) and without any marker of Kidney damage, It is recommended to measure eGFR with Cystatin C for confirmation of CKD

4. eGFR category G1 OR G2 does not fullfill the criteria for CKD, in the absence of evidence of Kidney Damage 5. In a suspected case of Acute Kidney Injury (AKI), measurement of eGFR should be done after 48-96 hours of any Intervention or procedure 6. eGFR calculated by Serum Creatinine may be less accurate due to certain factors like Race, Muscle Mass, Diet, Certain Drugs. In such cases, eGFR should be calculated using Serum Cystatin C 7. A decrease in eGFR implies either progressive renal disease, or a reversible process causing decreased nephron function (eg, severe dehydration).

ADVICE:

KDIGO guideline, 2012 recommends Chronic Kidney Disease (CKD) should be classified based on cause, eGFR category and Albuminuria (ACR) category. GFR & ACR category combined together reflect risk of progression and helps Clinician to identify the individual who are progressing at more rapid rate than anticipated



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME : Mrs. DARSHANA SHARMA **AGE/ GENDER** : 63 YRS/FEMALE **PATIENT ID** :1612757 **COLLECTED BY** REG. NO./LAB NO. :122504050013 **REFERRED BY REGISTRATION DATE** :05/Apr/2025 11:18 AM **BARCODE NO.** :12507915 **COLLECTION DATE** :05/Apr/2025 11:37AM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE **REPORTING DATE** :05/Apr/202503:59PM **CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA Value Unit Test Name **Biological Reference interval IMMUNOPATHOLOGY/SEROLOGY C-REACTIVE PROTEIN (CRP)** C-REACTIVE PROTEIN (CRP) QUANTITATIVE: 2.03 mg/L 0.0 - 6.0 SERUM by NEPHLOMETRY **INTERPRETATION:** 1. C-reactive protein (CRP) is one of the most sensitive acute-phase reactants for inflammation. 2. CRP levels can increase dramatically (100-fold or more) after severe trauma, bacterial infection, inflammation, surgery, or neoplastic proliferation. 3. CRP levels (Quantitative) has been used to assess activity of inflammatory disease, to detect infections after surgery, to detect transplant rejection, and to monitor these inflammatory processes. 4. As compared to ESR, CRP shows an earlier rise in inflammatory disorders which begins in 4-6 hrs, the intensity of the rise being higher than ESR

4. As compared to ESR, CRP shows an earlier rise in inflammatory disorders which begins in 4-6 hrs, the intensity of the rise being higher than ESR and the recovery being earlier than ESR. Unlike ESR, CRP levels are not influenced by hematologic conditions like Anemia, Polycythemia etc., 5. Elevated values are consistent with an acute inflammatory process.

1. Elevated C-reactive protein (CRP) values are nonspecific and should not be interpreted without a complete clinical history.

2. Oral contraceptives may increase CRP levels.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)





: Mrs. DARSHANA SHARMA

PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

AGE/ GENDER	: 63 YRS/FEMALE	PATIENT	ID	: 1612757
COLLECTED BY	:	REG. NO./	LAB NO.	: 122504050013
REFERRED BY	:	REGISTRA	ATION DATE	: 05/Apr/2025 11:18 AM
BARCODE NO.	: 12507915	COLLECT	ION DATE	: 05/Apr/2025 11:37AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INST	ITUTE REPORTI	NG DATE	: 05/Apr/2025 01:24PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AM	BALA CITY - HARYANA		
Test Name		Value	Unit	Biological Reference interv
	(CLINICAL PATHO	DLOGY	
	URINE ROUT	FINE & MICROSCO	PIC EXAMI	NATION
PHYSICAL EXAM	INATION			
QUANTITY RECIEV by DIP STICK/REFLEC	VED TANCE SPECTROPHOTOMETRY	15	ml	
COLOUR by DIP STICK/REFLEC	TANCE SPECTROPHOTOMETRY	PALE YELLOW		PALE YELLOW
TRANSPARANCY by DIP STICK/REFLEC	TANCE SPECTROPHOTOMETRY	HAZY		CLEAR
-	TANCE SPECTROPHOTOMETRY	1.02		1.002 - 1.030
CHEMICAL EXAN	<u>IINATION</u>			
REACTION	TANCE SPECTROPHOTOMETRY	ACIDIC		
PROTEIN	TANCE SPECTROPHOTOMETRY	NEGATIVE (-ve)		NEGATIVE (-ve)
SUGAR	TANCE SPECTROPHOTOMETRY	NEGATIVE (-ve)		NEGATIVE (-ve)
pH by DIP STICK/REFLEC	TANCE SPECTROPHOTOMETRY	5.5		5.0 - 7.5
BILIRUBIN by DIP STICK/REFLEC	TANCE SPECTROPHOTOMETRY	NEGATIVE (-ve)		NEGATIVE (-ve)
-	TANCE SPECTROPHOTOMETRY.	NEGATIVE (-ve)		NEGATIVE (-ve)
	TANCE SPECTROPHOTOMETRY	NOT DETECTED	EU/dL	0.2 - 1.0
•	TANCE SPECTROPHOTOMETRY	NEGATIVE (-ve)		NEGATIVE (-ve)
	TANCE SPECTROPHOTOMETRY	NEGATIVE (-ve)		NEGATIVE (-ve)
,	TANCE SPECTROPHOTOMETRY	NEGATIVE (-ve)		NEGATIVE (-ve)
MICROSCOPIC EX	<u>XAMINATION</u>			



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA

CONSULTANT PATHOLOGIST



A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. DARSHANA SHARMA				
AGE/ GENDER	: 63 YRS/FEMALE	PATIENT ID	: 1612757		
COLLECTED BY	:	REG. NO./LAB NO.	: 122504050013		
REFERRED BY	:	REGISTRATION DATE	: 05/Apr/2025 11:18 AM		
BARCODE NO.	: 12507915	COLLECTION DATE	:05/Apr/2025 11:37AM		
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	:05/Apr/202501:24PM		
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA				
Test Name	Value	Unit	Biological Reference interval		

	, uiuv	eme	Diological Interest entres was
RED BLOOD CELLS (RBCs) by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)	/HPF	0 - 3
PUS CELLS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	12-15	/HPF	0 - 5
EPITHELIAL CELLS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	4-6	/HPF	ABSENT
CRYSTALS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
CASTS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
BACTERIA by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
OTHERS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
TRICHOMONAS VAGINALIS (PROTOZOA) by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	ABSENT		ABSENT

*** End Of Report



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

